September 16, 2024
OncoBone has selected PharmaLegacy Laboratories, a preclinical CRO located in Shanghai, China as its partner for OncoBone’s preclinical Bone Metastasis Technology Platform (BMTP). OncoBone will utilize its Virtual CRO concept in the partnership.
BMTP is a predictive tool for evaluating drug efficacy on bone metastases before moving to clinical development, and it is expected to substantially decrease the current >95% chance of failure in clinical trials for oncology drugs, the failures causing $50 – 60 billion annual costs to pharma industry and its investors.
Jussi Halleen, CEO of OncoBone says: “It is a great pleasure to collaborate with PharmaLegacy. With their strong expertise in oncology and bone diseases, PharmaLegacy is an ideal partner for OncoBone and our BMTP.”
Michael Zhang, Sr.VP of PharmaLegacy comments: “I wish to thank OncoBone for their trust in partnering with PharmaLegacy and establishing the Bone Metastasis Technology Platform in our laboratory. We look forward to a long mutually beneficial collaboration with OncoBone”.
Michael Zhang, Sr.VP of PharmaLegacy and Jussi Halleen, CEO of OncoBone in premises of PharmaLegacy in Shanghai.
If you are interested to learn more,
see our services or contact us directly.
